We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
+31.25%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$2.67B
AUM Growth
+$753M
Cap. Flow
-$42M
Cap. Flow %
-1.57%
Top 10 Hldgs %
54.38%
Holding
380
New
93
Increased
88
Reduced
106
Closed
73

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$10.1M
2
CYTR
CytRx Corp
CYTR
+$5.67M
3
CELG
Celgene Corp
CELG
+$4.08M
4
UTHR icon
United Therapeutics
UTHR
+$3.38M
5
DVAX
Dynavax Technologies
DVAX
+$3.33M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$7.47M
2
ABT icon
Abbott
ABT
+$6.5M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$4.84M
4
NVIV
InVivo Therapeutics Holdings Corp
NVIV
+$3.87M
5
AMGN icon
Amgen
AMGN
+$3.54M

Sector Composition

Rank Sector Weight
1 Miscellaneous 90.18%
2 Healthcare 9.66%
3 Technology 0.11%
4 Consumer Staples 0.04%
5 Industrials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INFI
301
CALL
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$26K ﹤0.01%
167
– –
EYEGW
302
DELISTED
Eyegate Pharmaceuticals, Inc. Warrants
EYEGW
$16K ﹤0.01%
46,968
-6,925
-13% -$3.55K
LRMR icon
303
CALL
Larimar Therapeutics
LRMR
$406M
$15K ﹤0.01%
179
+101
+129% +$4.59K
ABEO icon
304
Abeona Therapeutics
ABEO
$313M
– –
-10,800
Closed -$637K
ACAD icon
305
CALL
Acadia Pharmaceuticals
ACAD
$4.61B
– –
-4,674
Closed -$15.2M
ACAD icon
306
PUT
Acadia Pharmaceuticals
ACAD
$4.61B
– –
-495
Closed -$1.61M
ACRS icon
307
Aclaris Therapeutics
ACRS
$814M
– –
-15,812
Closed -$292K
ADMA icon
308
ADMA Biologics
ADMA
$1.93B
– –
-100,000
Closed -$595K
AKBA icon
309
CALL
Akebia Therapeutics
AKBA
$250M
– –
-100
Closed -$75K
BIIB icon
310
Biogen
BIIB
$31.9B
– –
-10,000
Closed -$2.96M
COLL icon
311
Collegium Pharmaceutical
COLL
$711M
– –
-101,410
Closed -$1.2M
DXCM icon
312
PUT
DexCom
DXCM
$32.6B
– –
-16,856
Closed -$33.4M
FOLD
313
DELISTED
Amicus Therapeutics
FOLD
– –
-125,912
Closed -$850K
GLD icon
314
CALL
SPDR Gold Trust
GLD
$145B
– –
-1,000
Closed -$12.7M
ILMN icon
315
Illumina
ILMN
$33.6B
– –
-20,560
Closed -$2.81M
INSM icon
316
Insmed
INSM
$26.2B
– –
-43,964
Closed -$550K
JNJ icon
317
CALL
Johnson & Johnson
JNJ
$644B
– –
-2,809
Closed -$34.1M
LPCN icon
318
Lipocine
LPCN
$18.1M
– –
-3,757
Closed -$194K
MCRB icon
319
CALL
Seres Therapeutics
MCRB
$46.2M
– –
-2
Closed -$142K
MCRB icon
320
Seres Therapeutics
MCRB
$46.2M
– –
-1,030
Closed -$598K
NERV icon
321
Minerva Neurosciences
NERV
$183M
– –
-4,750
Closed -$388K
NVAX icon
322
Novavax
NVAX
$1.52B
– –
-7,136
Closed -$921K
OPK icon
323
Opko Health
OPK
$1.17B
– –
-190,554
Closed -$1.9M
PFE icon
324
CALL
Pfizer
PFE
$157B
– –
-10,540
Closed -$35.2M
PGEN icon
325
Precigen
PGEN
$2.51B
– –
-121,442
Closed -$2.96M
11 12
13
14 15

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q3 2016 Portfolio in Review

As of Q3 2016, Sabby Management held 380 positions worth $2.67B, up 39% from $1.92B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Sabby Management's Q3 2016 filing shows 93 new, 88 increased, 106 reduced and 73 closed positions. Its largest new stake was Bristol-Myers Squibb: 156,887 shares worth $8.46M. The largest sale was Sarepta Therapeutics, an estimated $7.47M.

By sector, the portfolio is most concentrated in Miscellaneous at 90% of assets, up from 86% a quarter earlier, followed by Healthcare and Technology.

  • Sabby Management's largest Q3 2016 buy was Bristol-Myers Squibb: 156,887 shares worth $8.46M.
  • Sabby Management added most to Dynavax Technologies in Q3 2016, an estimated $3.33M increase.
  • Sabby Management's biggest Q3 2016 reduction was Sarepta Therapeutics, cutting an estimated $7.47M.
  • Sabby Management fully exited Global Blood Therapeutics, Inc. in Q3 2016, selling an estimated $4.84M.
  • Sabby Management's ten largest holdings make up 54% of its $2.67B portfolio in Q3 2016.
  • Sabby Management opened 93 new positions and closed 73 in Q3 2016.
  • Sabby Management's portfolio value rose 39% quarter-over-quarter to $2.67B.

Based on Sabby Management's 13F filing for Q3 2016, filed 14 Nov 2016.